Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

The majority of multiple myeloma (MM) patients are 65 years of age or older at diagnosis [1]. However, treatment of MM in the elderly remains challenging because older patients typically have a hig...